= Bioassay parallelism
\b[Bioassay parallelism] is the common-shape relationship in which test and reference <dose-response relationships> differ only by a constant horizontal shift on a logarithmic concentration axis. Under that relationship, <relative biological potency> is independent of which response level is used for an equal-effect comparison. “Parallel” refers to a specified response model; it need not mean two straight lines on the original concentration scale.
For an original sigmoid model, write $z=\log x$ and
$$
f_j(z)=L+\frac{U-L}{1+e^{-b(z-m_j)}},\qquad j\in\{R,T\}.
$$
Common lower response $L$, upper response $U$ and slope parameter $b>0$ give parallel curves; different midpoints $m_R,m_T$ give relative potency $\rho=e^{m_R-m_T}$. Only the horizontal location changes. The <logistic function> provides the common mathematical shape, while experimental suitability determines whether it describes the biological observations.
An original equal-effect example uses $y_R(x)=x/(10+x)$ and $y_T(x)=x/(5+x)$. Their concentration ratio at every response strictly between zero and one is $x_R/x_T=2$. By contrast, replace the test curve with $x^2/(100+x^2)$. The reference and test now have the same half-response concentration, 10, but their equal-effect ratios are 0.5 at response 0.2 and 2 at response 0.8. A single midpoint ratio would conceal nonparallelism.
\Image[/bioassay-parallelism.png]
{title=Original stipulated response curves: a common log-concentration shape gives constant equal-effect potency, while different slopes give response-dependent ratios}
Practical evidence for similarity requires more than a nonsignificant difference test. A <bioassay parallelism equivalence margin> specifies how much departure is acceptable for the intended assay. An <equivalence test> can then ask whether the uncertainty interval lies within that prespecified range. For an illustrative acceptable slope-ratio range 0.8–1.25, an interval 0.9–1.1 supports that slope criterion; an interval 0.6–1.4 does not. These numbers are hypothetical design choices, not universal pharmaceutical limits. For nonlinear curves, agreement of the upper and lower responses matters as well as slope.
A primary USP application note describes <etanercept> activity through neutralization of <TNF-alpha> in <L929 cells>, using a multiwell <cell viability> readout, and identifies establishment of equivalence limits for parallelism as one use of its reference standard.<Etanercept for Bioassays reference-standard application note by United States Pharmacopeia>[How and when to use the etanercept bioassays reference standard; Figure 2]{ref} This illustrates an experimental response chain rather than merely fitting arbitrary curves.
Test and reference should be distributed across the relevant concentration range, with procedural controls, biological replication and recorded dilution preparation. Plate position, cell condition and <serial dilution> errors can generate structured differences. A common-shape fit imposed from the start cannot independently demonstrate that the shapes were sufficiently similar. Distinguish a useful potency model from evidence that its assumptions hold.
Back to article page
